Want to see HK:6086 full AI Analyst Report?
6086 Stock Chart & Stats
HK$3.63
HK$0.21(4.98%)
At close: 4:00 PM EST
HK$3.63
HK$0.21(4.98%)
Day’s Range― - ―
52-Week RangeHK$0.65 - HK$5.26
Previous CloseN/A
Volume737.00K
Average Volume (3M)2.01M
Market Cap
HK$990.60M
Enterprise ValueHK$834.51M
Total Cash (Recent Filing)HK$377.52M
Total Debt (Recent Filing)HK$35.81M
Price to Earnings (P/E)70.1
Beta1.76
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,385,448,500
10 Day Avg. Volume2,214,042
30 Day Avg. Volume2,011,125
Financial Highlights & Ratios
PEG Ratio-2.25
Price to Book (P/B)17.52
Price to Sales (P/S)0.76
P/FCF Ratio41.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)HK$4.69B
Bulls Say, Bears Say
Bulls Say
Return To ProfitabilityFangzhou's 2025 turnaround — revenue growth near 19% and a return to operating profit and net income — strengthens its ability to internally fund operations and R&D. Sustained profitability reduces reliance on external capital and supports strategic execution over the next several quarters.
Improved Cash GenerationMaterially positive operating and free cash flow in 2025 signals better earnings quality and working-capital management. Durable cash generation enhances financial flexibility to invest in pipeline development, service debt, and fund commercialization initiatives without immediate external financing.
Lower Leverage And Positive EquityA more manageable leverage profile and positive equity in 2025 improve solvency and reduce short-term refinancing risk. This balance-sheet stability supports sustained investment in operations and partnerships, and provides a buffer if near-term profitability fluctuates.
Bears Say
Very Thin Net MarginsNet margins near zero limit the company's capacity to absorb cost increases or invest heavily in growth. Even with positive net income, such thin margins leave earnings vulnerable to pricing pressure or higher R&D and SG&A, threatening durable earnings expansion over the medium term.
Eroding Gross MarginsA declining gross-margin trend suggests rising COGS or unfavorable product mix, undermining long-term scalability. For a drug manufacturer, persistent gross-margin erosion can squeeze operating profits and cash flow, making margin recovery and sustainable growth more difficult.
Historical Balance-sheet VolatilityPast periods of negative equity and balance-sheet swings indicate governance and capital-structure vulnerability. This history raises the risk of future recapitalization needs or dilutive financings if margins or cash flow slip, limiting the durability of recent improvements.
Fangzhou Inc. News
6086 FAQ
What was Fangzhou Inc.’s price range in the past 12 months?
Fangzhou Inc. lowest stock price was HK$0.65 and its highest was HK$5.26 in the past 12 months.
What is Fangzhou Inc.’s market cap?
Fangzhou Inc.’s market cap is HK$990.60M.
When is Fangzhou Inc.’s upcoming earnings report date?
Fangzhou Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 22 days.
How were Fangzhou Inc.’s earnings last quarter?
Fangzhou Inc. released its earnings results on Mar 19, 2026. The company reported HK$0 earnings per share for the quarter, the consensus estimate of N/A by HK$0.
Is Fangzhou Inc. overvalued?
According to Wall Street analysts Fangzhou Inc.’s price is currently Overvalued.
Does Fangzhou Inc. pay dividends?
Fangzhou Inc. does not currently pay dividends.
What is Fangzhou Inc.’s EPS estimate?
Fangzhou Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fangzhou Inc. have?
Fangzhou Inc. has 1,385,448,500 shares outstanding.
What happened to Fangzhou Inc.’s price movement after its last earnings report?
Fangzhou Inc. reported an EPS of HK$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went down -6.04%.
Which hedge fund is a major shareholder of Fangzhou Inc.?
Currently, no hedge funds are holding shares in HK:6086
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fangzhou Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
28.27%
Trailing 12-Months
Company Description
Fangzhou Inc.
Headquartered in Guangzhou, China, Fangzhou Inc. delivers comprehensive online chronic disease management services throughout the nation. The company leverages its dedicated digital platform to assist individuals grappling with long-term health issues like hypertension, cardiovascular, and respiratory conditions. Its mobile application facilitates a suite of "H2H" services, comprising virtual medical consultations, e-prescribing, and prescription renewal options. Furthermore, Fangzhou provides healthcare products through an online retail pharmacy and manages its own network of hospitals and brick-and-mortar pharmacies. The company was established in 2015.
Technical Analysis
Dingdang Health Technology Group Ltd.
―
CANbridge Pharmaceuticals Inc.
―
Modern Chinese Medicine Group Co. Ltd.
―
Sunho Biologics,Inc.
―
Beijing Biostar Pharmaceuticals Co., Ltd. Class H
―